ARCT
Price
$9.48
Change
-$0.72 (-7.06%)
Updated
Apr 3 closing price
Capitalization
257.23M
38 days until earnings call
CORT
Price
$79.37
Change
-$4.44 (-5.30%)
Updated
Apr 3 closing price
Capitalization
8.38B
26 days until earnings call
Ad is loading...

ARCT vs CORT

Header iconARCT vs CORT Comparison
Open Charts ARCT vs CORTBanner chart's image
Arcturus Therapeutics Holdings
Price$9.48
Change-$0.72 (-7.06%)
Volume$362.42K
Capitalization257.23M
Corcept Therapeutics
Price$79.37
Change-$4.44 (-5.30%)
Volume$2.09M
Capitalization8.38B
ARCT vs CORT Comparison Chart
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CORT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. CORT commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and CORT is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (ARCT: $9.48 vs. CORT: $79.37)
Brand notoriety: ARCT and CORT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 83% vs. CORT: 135%
Market capitalization -- ARCT: $257.23M vs. CORT: $8.38B
ARCT [@Biotechnology] is valued at $257.23M. CORT’s [@Biotechnology] market capitalization is $8.38B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileCORT’s FA Score has 2 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • CORT’s FA Score: 2 green, 3 red.
According to our system of comparison, CORT is a better buy in the long-term than ARCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while CORT’s TA Score has 6 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 4 bearish.
  • CORT’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, CORT is a better buy in the short-term than ARCT.

Price Growth

ARCT (@Biotechnology) experienced а -20.96% price change this week, while CORT (@Biotechnology) price change was +40.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

ARCT is expected to report earnings on May 12, 2025.

CORT is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CORT($8.38B) has a higher market cap than ARCT($257M). CORT YTD gains are higher at: 57.511 vs. ARCT (-44.107). CORT has higher annual earnings (EBITDA): 138M vs. ARCT (-77.4M). CORT has more cash in the bank: 383M vs. ARCT (237M). CORT has less debt than ARCT: CORT (6.94M) vs ARCT (28.6M). CORT has higher revenues than ARCT: CORT (675M) vs ARCT (138M).
ARCTCORTARCT / CORT
Capitalization257M8.38B3%
EBITDA-77.4M138M-56%
Gain YTD-44.10757.511-77%
P/E RatioN/A64.59-
Revenue138M675M20%
Total Cash237M383M62%
Total Debt28.6M6.94M412%
FUNDAMENTALS RATINGS
ARCT vs CORT: Fundamental Ratings
ARCT
CORT
OUTLOOK RATING
1..100
5687
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
85
Overvalued
PROFIT vs RISK RATING
1..100
10011
SMR RATING
1..100
9640
PRICE GROWTH RATING
1..100
9534
P/E GROWTH RATING
1..100
994
SEASONALITY SCORE
1..100
5043

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (49) in the Pharmaceuticals Major industry is somewhat better than the same rating for CORT (85) in the Pharmaceuticals Other industry. This means that ARCT’s stock grew somewhat faster than CORT’s over the last 12 months.

CORT's Profit vs Risk Rating (11) in the Pharmaceuticals Other industry is significantly better than the same rating for ARCT (100) in the Pharmaceuticals Major industry. This means that CORT’s stock grew significantly faster than ARCT’s over the last 12 months.

CORT's SMR Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for ARCT (96) in the Pharmaceuticals Major industry. This means that CORT’s stock grew somewhat faster than ARCT’s over the last 12 months.

CORT's Price Growth Rating (34) in the Pharmaceuticals Other industry is somewhat better than the same rating for ARCT (95) in the Pharmaceuticals Major industry. This means that CORT’s stock grew somewhat faster than ARCT’s over the last 12 months.

CORT's P/E Growth Rating (4) in the Pharmaceuticals Other industry is significantly better than the same rating for ARCT (99) in the Pharmaceuticals Major industry. This means that CORT’s stock grew significantly faster than ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTCORT
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
69%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 11 days ago
82%
Bullish Trend 11 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 2 days ago
66%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 3 days ago
68%
View a ticker or compare two or three
Ad is loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CORT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TILRX25.59N/A
N/A
Nuveen Large Cap Growth R
FIICX16.58N/A
N/A
Fidelity Advisor Mid Cap II C
GMXRX14.74N/A
N/A
Nationwide Mid Cap Market Idx R
PAHWX7.66N/A
N/A
PGIM Jennison Intl Sm-Md Cap Opps A
SVXCX53.92N/A
N/A
Smead International Value C